Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Journal Scan / Research · May 05, 2022

Efficacy and Cost-Efficiency of Immunologically Targeted Low-Dose Rituximab Protocol vs Conventional Rheumatoid Arthritis Protocol in Severe Pemphigus

Clinical and Experimental Dermatology


Additional Info

Clinical and Experimental Dermatology
Comparison of efficacy and cost-efficiency of an immunologically targeted low dose rituximab protocol with the conventional rheumatoid arthritis protocol in severe pemphigus
Clin Exp Dermatol 2022 Apr 05;[EPub Ahead of Print], N Singh, S Handa, R Mahajan, N Sachdeva, D De

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading